Pharma Focus Asia

Solasia Pharma and Meiji Seika Pharma Announce License and Distribution Agreement for episil® (oral liquid)

Monday, December 05, 2016

Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) announced today that Solasia and Meiji Seika Pharma Co. Ltd., (Headquarters: Tokyo, Japan, President: Daikichiro Kobayashi, hereinafter “Meiji”) have entered into a license and distribution agreement for the commercialization of episil® (SP-03) in Japan.

Under the terms of this agreement, Solasia will target to obtain approval for episil® for local treatment of pain associated with oral mucositis (OM) in Japan and thereafter Meiji will commercialize, distribute and promote episil®. In consideration of the license granted to Meiji, Solasia will receive upfront and milestone payments, as well as tiered royalties.

Solasia has obtained an exclusive license to develop and commercialize episil® in Japan and China from Camurus AB (“Camurus”) (STO: CAMX). In 2016, Solasia filed for New Medical Device Application for episil® (SP-03) in Japan and China.

episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM). Having been developed using the award-winning* Camurus proprietary technology FluidCrystal®, episil® is administered as lipid-based liquid that spreads on the intraoral mucosal surfaces and transforms to strongly bioadhesive film, which physically protects the sensitized and sore mucosa of the oral cavity. episil® has clinically demonstrated to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. episil® oral liquid is the only product for OM that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy. episil® was first launched in Europe in 2009 and is today commercially available in a number of countries, including the U.S. where it was launched by key global pharmaceutical players. episil® oral liquid is a medical device class 1 in Europe and a 510(k) registered medical device in the U.S.

 

Source:businesswire.com

 

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024